Merck’s Mevacor Returns For OTC Switch Consideration
Merck is in discussions with potential marketing partners for its third Rx-to-OTC switch attempt for the statin Mevacor, as the date approaches for an FDA advisory committee review of the drug
Merck is in discussions with potential marketing partners for its third Rx-to-OTC switch attempt for the statin Mevacor, as the date approaches for an FDA advisory committee review of the drug